NEW YORK, Aug. 16, 2012 /PRNewswire/ -- The Mangrove Partners Fund, L.P., one of Nabi Biopharmaceuticals' largest stockholders, today announced that it has delivered a letter to the stockholders of Nabi Biopharmaceuticals (Nasdaq: NABI).
The full text of the letter follows:
August 16, 2012
Dear Fellow Stockholders:
Your support in voting against the proposed merger (the "Transaction") between Nabi Biopharmaceuticals ("Nabi" or the "Company") and Biota Holdings Limited, a Melbourne, Australia company ("Biota") is crucial to defeating this value-destroying transaction. The Mangrove Partners Fund, L.P. and its affiliates ("Mangrove Partners") strongly oppose the proposed Transaction because it fails to return to Nabi's stockholders the underlying value of the Company's assets, a value that we believe to be as much as $2.40 per share in cash, while enriching Nabi executives at the expense of Nabi's stockholders.
Mangrove Partners strongly opposes the proposed Transaction and Transaction Proposals because we believe that:
- the proposed Transaction is an inferior alternative to several readily available alternatives that provide for the return of substantially all of the cash on the Company's balance sheet to Nabi's stockholders;
- Nabi's stockholders are being asked to invest in a speculative Australian biotechnology company that has lost money for the past two years and where the future leadership is uncertain; and
- the interests of Nabi management and the Nabi Board are not aligned with the best interests of stockholders in connection with the proposed Transaction.
In fact, Mangrove Partners believes the Transaction's primary purposes are (1) to secure substantial payments in the form of special VIP bonuses and change of control benefits for Nabi's executives and (2) to grant Nabi's CEO, Dr. Raafat Fahim, and Chairman, Dr. Geoffrey C
'/>"/>
SOURCE The Mangrove Partners Fund, L.P. Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
ACORN Research, LLC Announces Partnership with AdeptBio, LLC2.
Dicom Systems and USARAD.com Announce Partnership and Introduce Beta Version of XMRI.com, New System by USARAD.com3.
Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference4.
Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers5.
BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research6.
Cowen Healthcare Royalty Partners Raises $1 Billion7.
Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China8.
CoreLab Partners Opens Office in Tokyo, Japan9.
Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award10.
JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles11.
RiverVest Venture Partners Sells Four Successful Life Science Companies for More than $1 Billion